Patents not current catalysts, but this one may be signifcant if allowed
977 is on deck and may turn out to be very significant. Its a patent app to use a pharmaceutical composition patent for increasing serum EPA . Note its devoid of lowering TGs, LDL-C, inflammation markers etc. Its simply increasing serum EPA by 200% - 400% which is very broad and non specific to any indication. W currently hold a composition patent for pure EPA until 2020. This could be another barrier for 96% pure EPA but extedned until 2030.
Here is the claim:
1. A method of increasing plasma and/or serum EPA in a subject in need thereof, the method comprising administering, daily, to the subject a pharmaceutical composition comprising at least 96%, by weight, ethyl eicosapentaenoate, about 0.2% to about 0.5% by weight ethyl octadecatetraenoate, about 0.05% to about 0.25% by weight ethyl nonaecapentaenoate, about 0.2% to about 0.45% by weight ethyl arachidonate, about 0.3% to about 0.5% by weight ethyl eicosatetraenoate, about 0.05% to about 0.32% ethyl heneicosapentaenoate and not more than 0.05% ethyl-DHA, if any, in an amount sufficient to increase plasma and/or serum EPA levels in the subject by at least about 200% to compared to baseline.